Inmune Bio Stock Investor Sentiment
| INMB Stock | USD 8.14 0.17 2.05% |
About 55% of INmune Bio's investor base is interested to short. The analysis of the overall investor sentiment regarding INmune Bio suggests that many traders are impartial. The current market sentiment, together with INmune Bio's historical and current headlines, can help investors time the market. In addition, many technical investors use INmune Bio stock news signals to limit their universe of possible portfolio assets.
INmune |
INmune Bio Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards INmune Bio can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about INmune Bio that are available to investors today. That information is available publicly through INmune media outlets and privately through word of mouth or via INmune internal channels. However, regardless of the origin, that massive amount of INmune data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of INmune Bio news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of INmune Bio relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to INmune Bio's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive INmune Bio alpha.
INmune Bio Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Acquisition by Allen Marcia of 32500 shares of INmune Bio at 5.05 subject to Rule 16b-3 | 12/20/2024 |
2 | Acquisition by Lowdell Mark William of 14423 shares of INmune Bio at 8.32 subject to Rule 16b-3 | 12/31/2024 |
3 | INmune Bio Insiders Added US902.6k Of Stock To Their Holdings | 01/23/2025 |
4 | Acquisition by Moss David J of 160000 shares of INmune Bio at 9.92 subject to Rule 16b-3 | 01/24/2025 |
5 | INmune Bio Inc. Expands INKmune Trial in Prostate Cancer to Veterans | 01/28/2025 |
6 | Acquisition by Xencor Inc of 192533 shares of INmune Bio at 17.14 subject to Rule 16b-3 | 01/30/2025 |
7 | Acquisition by Schroeder Timothy J of 12500 shares of INmune Bio at 9.92 subject to Rule 16b-3 | 01/31/2025 |
8 | Why INmune Bio Inc Is Skyrocketing So Far In 2025 | 02/04/2025 |
9 | INmune Bio Announces Plan to Submit FDA Biologics License Application Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa | 02/10/2025 |
10 | INmune Bio Price Target Raised to 23.00 at Scotiabank | 02/12/2025 |
11 | Is INmune Bio A Risky Investment | 02/27/2025 |
12 | INmune Bio Reports Promising Phase III Trial Results - TipRanks | 03/04/2025 |
13 | Acquisition by Baracchini Edgardo Jr of 35000 shares of INmune Bio subject to Rule 16b-3 | 03/05/2025 |
14 | Acquisition by Lowdell Mark William of 140000 shares of INmune Bio at 5.05 subject to Rule 16b-3 | 03/07/2025 |
15 | INmune Bio CORDStrom Is A Game-Changer, As Investors Await Alzheimers Results - Seeking Alpha | 03/18/2025 |
Complementary Tools for INmune Stock analysis
When running INmune Bio's price analysis, check to measure INmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy INmune Bio is operating at the current time. Most of INmune Bio's value examination focuses on studying past and present price action to predict the probability of INmune Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move INmune Bio's price. Additionally, you may evaluate how the addition of INmune Bio to your portfolios can decrease your overall portfolio volatility.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |